Oroxylum indicum Extract, at a Physiologically Relevant Dosage, Does Not Induce Hepatotoxicity in C57BL/6J Mice

Satyanarayana R. Pondugula1, Julia M. Salamat1, Kodye L. Abbott1, Patrick C. Flannery1, Mohammed Majrashi2,3, Mohammed Almaghrabi2, Manoj Govindarajulu2, Sindhu Ramesh2, Suneel K. Onteru4, Maninder Sandey5, Chen-Che J. Haung1, Kristina Gill1, Natasha Narayanan1, Edwin McElroy1, Darshini Desai2, Rishi Nadar2, Timothy Moore2, Nagabhushanam Kalyanam6, Mohammed Majeed6, and Muralikrishnan Dhanasekaran2

Abstract

Background: Botanical supplements have been proven to provide beneficial health effects. However, they can induce unintended adverse events such as hepatotoxicity. Oroxylum indicum extract (OIE, Sabroxy®) has several health benefits including anti-inflammatory, anti-arthritic, antifungal, antibacterial, and neuroprotective effects. It is currently unknown whether OIE has the potential to induce hepatotoxicity. Purpose: In the current study, we sought to determine whether OIE can induce hepatotoxicity in C57BL/6J mouse model. Methods: The male mice were fed powdered rodent food (control group) or powdered rodent food mixed with OIE (Sabroxy®, 500 mg/kg) daily for 4 weeks. Following the treatment, we assessed liver histology and serum levels of biomarkers commonly associated with liver damage, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP). Results: No significant alterations were observed in liver histology, and serum levels of ALT, AST, ALP, bilirubin, albumin, globulin, and total protein in the OIE fed mice compared to the control mice. Conclusion: Taken together, our results suggest that OIE, when fed at its physiologically relevant dosage, does not induce hepatotoxicity in C57BL/6J mice.

Keywords
alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, botanical supplement, hepatotoxicity, Oroxylum indicum

Received: February 5th, 2021; Accepted: April 22nd, 2021.

Botanical supplements (BS) are consumed globally as an alternative form of medicine, and are commonly acquired without any medical prescription.1 However, the majority of BS are not evaluated by regulatory bodies due to lack of federal regulations. Therefore, the exact makeup of ingredients in BS may not be described, resulting in uncertainty about the safety and toxicity of the majority of available BS. Although the full scope of BS-induced adverse effects remains to be determined, a number of reports showed an increasing incidence of BS-induced hepatotoxicity.2 For example, Camellia sinensis (green tea extract), Hydroxycut® (a proprietary blend of BS), and Garcinia cambogia have been shown to induce liver injury as exhibited by increases in serum markers of liver function.3 Clinical chemistry and histopathology are the mainstay to detect various types of hepatic injury in pre-clinical animal studies. For example, serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are routinely used to detect hepatocellular injury. Similarly, serum levels of

1Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, AL, USA
2Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, AL, USA
3Department of Pharmacology, Faculty of Medicine, University of Jeddah, Jeddah, Saudi Arabia
4Animal Biochemistry Division, National Dairy Research Institute, ICAR-NDSRI, Kamal, India
5Department of Pathobiology, College of Veterinary Medicine, Auburn University, AL, USA
6Sabinsa Corporation, East Windsor, NJ, USA

Corresponding Authors:
Muralikrishnan Dhanasekaran, Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA.
Email: dhanamu@auburn.edu
Satyanarayana R. Pondugula, Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA.
Email: srp0010@auburn.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
bilirubin and alkaline phosphatases are used to assess the hepatobiliary function. In addition, low levels of albumin, an important plasma protein produced by hepatocytes, may also indicate hepatic dysfunction.

Oroxylum indicum (OI) is a genus of medium-sized tree belonging to the plant family Bignoniaceae. It is native to tropical Asian countries, particularly India, Sri Lanka, Malaysia, China, Thailand, Philippines, and Indonesia. OI raw plant parts or OI extract (OIE) are commonly used in the traditional system of medicine for the prevention and treatment of several diseases. For example, OI has been shown to exhibit antidiabetic, anti-arthritis, anti-hyperlipidemic, antioxidant, anti-inflammatory, anticarcinogenic, antimicrobial, and anti-obesity activities in both in vivo and in vitro studies. OI has also been shown to protect against β-amyloid-induced cell injury and drug-induced renal injury.

While OI and OIE have been shown to exhibit many beneficial effects, their potential toxic effects are not fully understood. Here, we set to determine whether the administration of a commercially available OIE Sabroxy®, which contains standardized amounts of bioactive compounds, would induce hepatotoxicity in a rodent model by examining the key serum markers and histology indicative of liver injury.

Materials and Methods

Materials

OI extract (Sabroxy®) was provided by Sabinsa Corporation. The Oroxylum indicum bark extract used in this investigation was prepared using the methods described in US patent number: US10555982B2. The identified active compounds in this extract included Oroxylin A, Baicalein, and Chrysin.

Animals and Treatment

8 week old male C57BL/6J mice weighing 25-35 g were housed in a temperature-controlled room with a 12 hour day and night cycle with access to food and water ad libitum. The mice received humane care and in vivo experiments were carried after obtaining appropriate approvals from Auburn University’s Institutional Animal Care and Use Committee (IACUC). Health benefits of OIE were studied using orally administered doses ranging from 100 to 500 mg/kg/day of Sabroxy® in rodents. To determine the potential hepatotoxic effect of OIE, the treatment group mice (n = 6) were fed daily for 4 weeks with 500 mg/kg Sabroxy® mixed in the powdered rodent food. The control group of mice (n = 6) were fed the powdered rodent food without Sabroxy® for 4 weeks.

Tissue Collection and Processing

After 4 weeks of treatment, the mice from both groups were euthanized through CO₂ asphyxiation followed by secondary decapitation. Blood was collected immediately after decapitation and serum was separated for serum biomarker analysis. The mice livers were collected and processed for histological analysis.

Serum Biomarker Analysis

Serum ALT and AST concentrations were measured using a colorimetric enzymatic assay established and validated on the c 311 biochemistry analyzer (Roche, Indianapolis, Indiana) at the Auburn University Clinical Pathology Laboratory. Serum was also used to test for other markers indicative of hepatotoxicity such as total protein, albumin, and globulin. Serum ALP and bilirubin levels were also assessed using the same method used for ALT and AST measurement.

Liver Histology Analysis

The liver sections were collected from various liver lobes, fixed in 10% neutral buffered formalin and paraffin embedded. 5 µm thick liver sections were cut and stained with H&E for histological assessment.

Data and Statistical Analysis

Data are shown as mean values ± SEM. Analyses were performed using Prism-V software (La Jolla, CA, USA). The significance of the differences between groups was evaluated by Students t-test. P value of <0.05 were determined to be statistically significant.

Results

Effect of OIE Treatment on Liver Histology

OIE treatment did not result in a noticeable change in the liver histology as shown by H&E staining (Figure 1).

---

**Figure 1.** Effect of OIE treatment on liver histology. Liver sections of control (A) and OIE treated (B) mice were stained with H&E for histological assessment.
Effect of OIE Treatment on Serum Biomarkers of Liver Function

OIE treatment did not significantly alter the serum levels of ALT, AST, ALP, bilirubin, albumin, globulin, and total protein (Figure 2).

Discussion

In this study, we showed that the administration of Sabroxy® at the dose of 500 mg/kg/day for 4 weeks does not induce hepatotoxicity in C57BL/6J male mice. After treatment, there was no significant change in serum biomarkers including liver transaminases, albumin, bilirubin, and ALP which are commonly used to detect liver injury. Similarly, Sabroxy® supplementation did not lead to histopathological changes in the liver of mice.

Different parts of OI plant, including stem, bark, roots, leaves, and fruits have been shown to exhibit a variety of health benefits. OIE may display differential biological effects depending on the extraction method. One study evaluated the anti-arthritic activity of OI root extracts obtained using different solvents: chloroform, ethyl acetate, and n-butanol. All 3 extracts were administered into rats through the oral route at a dosage of 300 mg/kg. Results indicated that all 3 extracts exhibited anti-arthritic activity. However, the relative anti-arthritic activity was found to be highest in ethyl acetate extract (67.69%), followed by chloroform extract (64.61%), and lastly, n-butanol extract (58.46%). The differential effects of OIE could be due to the variation in the amounts of biologically active ingredients depending on the plant part and solvent used for extraction method. It is difficult to evaluate the hepatotoxicity of OIEs since OIEs can be obtained from various parts of the OI plant using different extraction methods. Therefore, having a standardized extract, such as Sabroxy®, with known amounts of biologically active compounds would be beneficial to understand the potential of OIE to induce hepatotoxicity.

Sabroxy® contains standardized amounts of the Oroxylin-A, Baicalein, and Chrysin. All 3 compounds show hepatoprotective effects in vivo. Oroxylin A, Baicalein, and Chrysin are flavonoids present in numerous plant extracts including OI, and were shown to suppress inflammation in mice with CCl4-induced acute liver failure and acetaminophen-exposed liver injury in mice. Our current study supports the above published studies, as Sabroxy® failed to cause hepatotoxic effects in the mice.

Due to the fact that the biomarkers were measured at one time point after a 4 week treatment period of OIE, this study is considered as a sub-acute study. Although we did not notice a significant hepatotoxicity at the end of 4 weeks of treatment, it can not be ruled out that the mice may have developed acute hepatic toxicity during the treatment period, and that the mice may have recovered from the early liver injury before our endpoint at 4 weeks when serum biomarkers were studied.

Although the dosage and frequency of administration of OIE used in our study is physiologically relevant, various doses from 100 to 500 mg/kg are typically used for varying treatment periods. Therefore, future studies in larger cohorts are warranted to determine the dosage and time-dependent hepatic effects of OIE administration to validate the potential hepatotoxicity of OIE. It is also important that future studies examine the levels and activities of markers of oxidative stress and inflammation in liver. Finally, our study included only male mice. It will be interesting to examine whether the effect of OIE administration is sexually dimorphic.

![Figure 2. Effect of OIE treatment on serum levels of ALT (A), AST (B), ALP (C), bilirubin (D), albumin (E), globulin (F), and total protein (G). Serum markers were analyzed from control (n = 6) and OIE treated mice (n = 6). Results are presented as mean values ± SEM. The significance of the differences between groups was evaluated by Students t-test. P < 0.05 values were determined to be statistically significant.](image-url)
Conclusion

Our results suggest that Sabroxy®, at its physiologically relevant dosage used for beneficial effects, does not induce hepatotoxicity in the mice after a 4 week treatment.

Acknowledgments

This project was supported by Sabinsa Corporation, Animal Health and Disease Research Grant and Auburn University Research Initiative in Cancer Grant.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Our institution does not require ethical approval for reporting individual cases or case series. Nagabhushanam K and Majeed M, are involved in designing the experiments and proofreading the manuscript. They did not involve in conducting the experiments and data analyses. All procedures in this study were conducted in accordance with the Auburn University’s Institutional Animal Care and Use Committee-IACUC, (2016-2978) approved protocols.

ORCID IDs

Mohammed Majrashi https://orcid.org/0000-0001-5752-7389
Chen-Che J. Haung https://orcid.org/0000-0003-0376-4682
Nagabhushanam Kalyanam https://orcid.org/0000-0001-9470-4110
Muralikrishnan Dhanasekaran https://orcid.org/0000-0001-8986-3440

References

1. Tarn DM, Paterniti DA, Good JS, et al. Physician-patient communication about dietary supplements. Patient Educ Couns. 2013;91(3):287-294. doi:10.1016/j.pec.2013.01.021
2. Navarro VJ, Khan I, Björnsson E, Sceff LB, Serrano J, Hoofnagle JH. Liver injury from herbal and dietary supplements. Hepatology. 2017;65(1):363-373. doi:10.1002/hep.28813
3. Stickel F, Shouval D. Hepatotoxicity of herbal and dietary supplements: an update. Arch Toxicol. 2015;89(6):851-865. doi:10.1007/s00204-015-1471-3
4. Thapa BR, Walia A. Liver function tests and their interpretation. Indian J Pediatr. 2007;74(7):663-671. doi:10.1007/s12098-007-0118-7
5. Gowda S, Desai PB, Hull VV, Math AAK, Vernekar SN, Kulkarni SS. A review on laboratory liver function tests. Pan Afr Med J. 2009;3:17.
6. Mishra SL, Sinhamahapatra PK, Nayak A, Das R, Sannigrahi S. In vitro antioxidant potential of different parts of Oroxylum indicum: a comparative study. Indian J Pharm Sci. 2010;72(2):267-269. doi:10.4103/0250-474X.65013
7. Dinda B, SilSarma I, Dinda M, Rudrapaul P. Oroxylum indicum (L.) Kurz, an important Asian traditional medicine: from traditional uses to scientific data for its commercial exploitation. J Ethnopharmacol. 2015;161(Suppl 1):255-278. doi:10.1016/j.jep.2014.12.027
8. Harminder, Singh V, Chaudhary AK. A review on the taxonomy, ethnombotany, chemistry and pharmacology of Oroxylum indicum vent. Indian J Pharm Sci. 2011;73(5):483-490. doi:10.4103/0250-474X.98981
9. Singh J, Kakkar P. Modulation of liver function, antioxidant responses, insulin resistance and glucose transport by Oroxylum indicum stem bark in STZ induced diabetic rats. Food Chem Toxicol. 2013;62:722-731. doi:10.1016/j.fct.2013.09.035
10. Karnati M, Chandra RH, Veeresham C, Kishan B. Anti-arthritis activity of root bark of Oroxylum indicum (L.) vent against adjuvant-induced arthritis. Pharmacogn Res. 2013;5(2):121-128. doi:10.4103/0974-8490.110543
11. Mangal P, Khare P, Jagtap S, Bishnoi M, Kondepudi KK, Bhutani KK. Screening of six ayurvedic medicinal plants for anti-obesity potential: an investigation on bioactive constituents from Oroxylum indicum (L.) Kurz bark. J Ethnopharmacol. 2017;197:138-146. doi:10.1016/j.jep.2016.07.070
12. Doshi K, Ilanchezhian R, Acharya R, Patel BR, Ravishankar B. Anti-inflammatory activity of root bark and stem bark of Shyonna. J Ayurveda Integr Med. 2012;3(4):194-197. doi:10.4103/0975-9476.104434
13. Naveen Kumar DR, Cijo George V, Suresh PK, Ashok Kumar R, George C. Cytoxicity, apoptosis induction and anti-metastatic potential of Oroxylum indicum in human breast cancer cells. Asian Pac J Cancer Prev. 2012;13(6):2729-2734. doi:10.7314/APJCP.2012.13.6.2729
14. Radhika LG, Meena CV, Peter S, Rajesh KS, Rosamma MP. Phytochemical and antimicrobial study of Oroxylum indicum. Anc Sci Life. 2011;30(4):114-120.
15. Hengpratom T, Lowe GM, Thuman K, Suknasang S, Tammyom K, Eumkeb G. Anti-amyloid activity of root bark of Oroxylum indicum (L.) vent against β-amyloid-induced cell injury. Mol Med Rep. 2019;20(2):1933-1942. doi:10.3892/mmr.2019.10443
16. Mairue N, Connor JR, Buranrat B, Lee SY. Oroxylum indicum (L.) extract protects human neuroblastoma SH-SY5Y cells against β-amyloid-induced cell injury. Mol Med Rep. 2019;20(2):1933-1942. doi:10.3892/mmr.2019.10411
17. Sultana S, Verma K, Khan R. Nephroprotective efficacy of chrysin against cisplatin-induced toxicity via attenuation of oxidative stress. J Pharm Pharmacol. 2012;64(6):872-881. doi:10.1111/j.2042-7158.2012.01470.x
18. Majeed M, Nagabhushanam K, Bhat B, Pande A, inventors; Composition containing oroxylin A and method of extraction thereof. USA 2020.
19. Tenpe C, Upaganlawar A, Burle S, Yeole Y. In vitro antioxidant and preliminary hepatoprotective activity of Oroxylum indicum vent leaf extracts. Pharmacognonline. 2009;1:35-43.
20. Begum MM, Islam A, Begum R, et al. Ethnopharmacological inspections of organic extract of Oroxylum indicum in rat models.
A promising natural gift. *Evid Based Complement Alternat Med.* 2019;2019:1-13. doi:10.1155/2019/1562038

21. Das BK, Al- Amin MM, Russel SM, Kabir S, Bhattacharjee R, Hannan JMA. Phytochemical screening and evaluation of analgesic activity of *Oroxylum indicum*. *Indian J Pharm Sci.* 2014;76(6):571-575.

22. Zhu R, Zeng G, Chen Y, et al. Oroxylin a accelerates liver regeneration in CCl₄-induced acute liver injury mice. *PLoS One.* 2013;8(8):e71612. doi:10.1371/journal.pone.0071612

23. Hermenean A, Mariasiu T, Navarro-González I, et al. Hepatoprotective activity of chrysin is mediated through TNF-α in chemically-induced acute liver damage: an in vivo study and molecular modeling. *Exp Ther Med.* 2017;13(5):1671-1680. doi:10.3892/etm.2017.4181

24. Zhou H-C, Wang H, Shi K, Li J-M, Zong Y, Du R. Hepatoprotective effect of baicalein against acetaminophen-induced acute liver injury in mice. *Molecules.* 2018;24(1):131. doi:10.3390/molecules24010131